Literature DB >> 27455875

Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.

Chih-Jian Lih1, Han Si1, Biswajit Das1, Robin D Harrington1, Kneshay N Harper1, David J Sims1, Paul M McGregor1, Corinne E Camalier1, Andrew Y Kayserian1, P Mickey Williams1, Hua-Jun He2, Jamie L Almeida2, Steve P Lund3, Steve Choquette2, Kenneth D Cole4.   

Abstract

The National Institute of Standards and Technology (NIST) Standard Reference Materials 2373 is a set of genomic DNA samples prepared from five breast cancer cell lines with certified values for the ratio of the HER2 gene copy number to the copy numbers of reference genes determined by real-time quantitative PCR and digital PCR. Targeted-amplicon, whole-exome, and whole-genome sequencing measurements were used with the reference material to compare the performance of both the laboratory steps and the bioinformatic approaches of the different methods using a range of amplification ratios. Although good reproducibility was observed in each next-generation sequencing method, slightly different HER2 copy numbers associated with platform-specific biases were obtained. This study clearly demonstrates the value of Standard Reference Materials 2373 as reference material and as a calibrator for evaluating assay performance as well as for increasing confidence in reporting HER2 amplification for clinical applications. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27455875      PMCID: PMC5397679          DOI: 10.1016/j.jmoldx.2016.05.008

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  44 in total

1.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

Authors:  Michael F Press; Dennis J Slamon; Kerry J Flom; Jinha Park; Jian-Yuan Zhou; Leslie Bernstein
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

2.  Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Authors:  Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

3.  The knowns and the unknowns in HER2 testing in breast cancer.

Authors:  Allen M Gown; Lynn C Goldstein
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

4.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV.

Authors:  Jarupon Fah Sathirapongsasuti; Hane Lee; Basil A J Horst; Georg Brunner; Alistair J Cochran; Scott Binder; John Quackenbush; Stanley F Nelson
Journal:  Bioinformatics       Date:  2011-08-09       Impact factor: 6.937

5.  Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.

Authors:  Victoria M Pratt; Robin E Everts; Praful Aggarwal; Brittany N Beyer; Ulrich Broeckel; Ruth Epstein-Baak; Paul Hujsak; Ruth Kornreich; Jun Liao; Rachel Lorier; Stuart A Scott; Chingying Huang Smith; Lorraine H Toji; Amy Turner; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2015-11-24       Impact factor: 5.568

Review 6.  Implementing personalized cancer genomics in clinical trials.

Authors:  Richard Simon; Sameek Roychowdhury
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Karyotypic complexity of the NCI-60 drug-screening panel.

Authors:  Anna V Roschke; Giovanni Tonon; Kristen S Gehlhaus; Nicolas McTyre; Kimberly J Bussey; Samir Lababidi; Dominic A Scudiero; John N Weinstein; Ilan R Kirsch
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

9.  Molecular cytogenetic analysis of breast cancer cell lines.

Authors:  J M Davidson; K L Gorringe; S F Chin; B Orsetti; C Besret; C Courtay-Cahen; I Roberts; C Theillet; C Caldas; P A Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  WaveCNV: allele-specific copy number alterations in primary tumors and xenograft models from next-generation sequencing.

Authors:  Carson Holt; Bojan Losic; Deepa Pai; Zhen Zhao; Quang Trinh; Sujata Syam; Niloofar Arshadi; Gun Ho Jang; Johar Ali; Tim Beck; John McPherson; Lakshmi B Muthuswamy
Journal:  Bioinformatics       Date:  2013-11-04       Impact factor: 6.937

View more
  11 in total

1.  A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.

Authors:  Steven A Bogen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-02-22

Review 2.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

3.  Limitations of methods for measuring the concentration of human genomic DNA and oligonucleotide samples.

Authors:  Hua-Jun He; Erica V Stein; Paul DeRose; Kenneth D Cole
Journal:  Biotechniques       Date:  2018-02-01       Impact factor: 1.993

4.  HER2 mRNA transcript quantitation in breast cancer.

Authors:  K Meehan; B Clynick; B Mirzai; P Maslen; J M Harvey; W N Erber
Journal:  Clin Transl Oncol       Date:  2016-11-11       Impact factor: 3.405

5.  Analytic Response Curves of Clinical Breast Cancer IHC Tests.

Authors:  Kodela Vani; Seshi R Sompuram; Anika K Schaedle; Anuradha Balasubramanian; Steven A Bogen
Journal:  J Histochem Cytochem       Date:  2017-01-01       Impact factor: 2.479

6.  Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.

Authors:  Yuefeng Wang; Julia Y S Tsang; Yongmei Cui; Ji Cui; Ying Lin; Songli Zhao; Patrick T W Law; Sai Yin Cheung; Enders K O Ng; Gary M K Tse; Zunfu Ke
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

7.  A model for the impact of FFPE section thickness on gene copy number measurement by FISH.

Authors:  Jiyan Yu; Qi Wang; Pu Xue; Li Zheng; Juanfen Mo; Liangye Chen; Manxiang Yin; Yueyan Huang; Yi Bao; Feng Ding
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

8.  Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements.

Authors:  Hua-Jun He; Biswajit Das; Megan H Cleveland; Li Chen; Corinne E Camalier; Liang-Chun Liu; Kara L Norman; Andrew P Fellowes; Christopher R McEvoy; Steve P Lund; Jamie Almeida; Carolyn R Steffen; Chris Karlovich; P Mickey Williams; Kenneth D Cole
Journal:  Clin Chem Lab Med       Date:  2019-07-26       Impact factor: 3.694

9.  Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer.

Authors:  Moushumi Suryavanshi; Jiten Jaipuria; Anurag Mehta; Dushyant Kumar; Manoj Kumar Panigrahi; Haristuti Verma; Mumtaz Saifi; Sanjeev Sharma; Simran Tandon; Dinesh Chandra Doval; Bhudev C Das
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec

10.  Lentiviral vector-based xenograft tumors as candidate reference materials for detection of HER2-low breast cancer.

Authors:  Yali Wei; Xu An; Qinmei Cao; Nanying Che; Yuanyuan Xue; Haiteng Deng; Qingtao Wang; Rui Zhou
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.